Fidaxomicin antibiotic (Dificid): Treatment for treatment of adults with Clostridium difficile-associated diarrhea

Formulary , 10/28/2011

On May 2011, FDA approved fidaxomicin for the treatment of adults with Clostridium difficile–associated diarrhea (CDAD). Fidaxomicin works by inhibiting RNA synthesis via RNA polymerases, and acts locally in the gastrointestinal tract to target C difficile with minimal systemic absorption. To prevent the development of drug–resistant bacteria, fidaxomicin should only be prescribed in the presence of proven or strongly suspected C difficile infection.

Print Article Summary Cat 2 CME Report